探索PD-MCI组中的临床变异和共同疾病趋势
K Ganapathy1, B Kumar2, Sh Shekhawat3
11Department of Biotechnology, School of Sciences, JAIN (Deemed-to-be University), Karnataka, India.
Georgian medical news
|December 14, 2023
概括
轻度认知障碍帕金森病 (PD-MCI) 显著影响视觉空间和执行功能. 特定的PD-MCI群体表现出明显的神经和运动缺陷,突出显示了病情的复杂性.
科学领域:
- 神经学 神经学
- 认知科学 认知科学
背景情况:
- 带有轻度认知障碍的帕金森病 (PD-MCI) 呈现出运动和认知缺陷.
- 了解PD-MCI中的特定认知和神经变异对于有针对性的干预至关重要.
研究的目的:
- 调查不同PD-MCI患者群体中不同的医疗指标和相关趋势.
- 确定PD-MCI中最受影响的认知领域和神经特征.
主要方法:
- 使用SPSS对132名PD-MCI患者的数据进行了统计分析.
- 进行认知和神经评估以确定群体变异.
主要成果:
- 视觉空间能力和注意力/执行功能是所有PD-MCI变体中最受损害的认知领域.
- 多域失忆症 (非记忆) PD-MCI患者表现出严重的姿势和行走问题.
结论:
- PD-MCI是一种复杂的疾病,具有多样化的认知和神经学特征.
- 在PD-MCI的认知和身体症状之间的相互作用受到特定的认知领域,大脑区域和整体损伤水平的影响.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.1K
相关概念视频
Parkinson's Disease: Overview
556
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
556
Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Diagnostic and Statistical Manual of Mental Disorders (DSM)
57
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
57
Parkinson's Disease: Treatment
274
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
274
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
